brief review on clinical pharmacy, drug information centre & patient safety program
The lecture was presented at Al-Mahmoudiya General Hospital as part of the training course for fresh appointed pharmacist at 16/5/2023 at 11 & 15/5/2023
brief review on clinical pharmacy, drug information centre & patient safety program
The lecture was presented at Al-Mahmoudiya General Hospital as part of the training course for fresh appointed pharmacist at 16/5/2023 at 11 & 15/5/2023
Apresentação realizada no I Seminário Internacional de Atenção às Condições Crônicas, pela diretora do Programa da Gestão de Doenças Crônica dos Serviços Sanitários De Alberta/Canadá, Sandra Delon.
Belo Horizonte, 11 de novembro de 2014
Health partners elluminate ppt_final_9.13.10CChangeProgram
C-Change (Communication for Change) is a USAID-fundd program to improve the effectiveness and sustainability of social and behavior change communication (SBCC) as an integral part of development efforts in malaria, HIV and AIDS, and family planning/reproductive health.
C-Change works with USAID and the President's Malaria Initiative (PMI) to prevent and control malaria in several PMI target countries, including Ethiopia, Kenya, Mozambique, Sao Tome and Principe, as well as others.
On September 13, 2010, C-Change and MCHIP facilitated a narrated presentation of the work of two PMI grantees, Concern Universal and HealthPartners, via a webinar. Participants included Save the Children, USAID, CDC, IFPH, and others.
For more information, please visit: http://www.c-changeprogram.org/
The all the content in this profile is completed by the teachers, students as well as other health care peoples.
thank you, all the respected peoples, for giving the information to complete this presentation.
this information is free to use by anyone.
Dr. Jeff Bender - One Health Antibiotic Stewardship Science and Practice - Wh...John Blue
One Health Antibiotic Stewardship Science and Practice - What are the Major Gaps in Knowledge or Translation? How Do We Find the Answers to What We Don't Know? - Dr. Kerry Keffaber, Chief Veterinarian, Scientific Affairs and Policy, Elanco Animal Health; Dr. Jeff Bender, Professor, Environmental Sciences, University of Minnesota; Dr. Nora Schrag, Clinical Assistant Professor/Agricultural Practices, Kansas State University; Mr. Joe Swedberg, Chairman of the Board, Farm Foundation, Hormel Foods Corporation (retired); Dr. David G. White, Associate Dean for Research, University of Tennessee Institute of Agriculture, from the 2017 NIAA Antibiotic Symposium - Antibiotic Stewardship: Collaborative Strategy for Animal Agriculture and Human Health, October 31 - November 2, 2017, Herndon, Virginia, USA.
More presentations at http://www.swinecast.com/2017-niaa-antibiotic-symposium-antibiotic-stewardship
Apresentação realizada no I Seminário Internacional de Atenção às Condições Crônicas, pela diretora do Programa da Gestão de Doenças Crônica dos Serviços Sanitários De Alberta/Canadá, Sandra Delon.
Belo Horizonte, 11 de novembro de 2014
Health partners elluminate ppt_final_9.13.10CChangeProgram
C-Change (Communication for Change) is a USAID-fundd program to improve the effectiveness and sustainability of social and behavior change communication (SBCC) as an integral part of development efforts in malaria, HIV and AIDS, and family planning/reproductive health.
C-Change works with USAID and the President's Malaria Initiative (PMI) to prevent and control malaria in several PMI target countries, including Ethiopia, Kenya, Mozambique, Sao Tome and Principe, as well as others.
On September 13, 2010, C-Change and MCHIP facilitated a narrated presentation of the work of two PMI grantees, Concern Universal and HealthPartners, via a webinar. Participants included Save the Children, USAID, CDC, IFPH, and others.
For more information, please visit: http://www.c-changeprogram.org/
The all the content in this profile is completed by the teachers, students as well as other health care peoples.
thank you, all the respected peoples, for giving the information to complete this presentation.
this information is free to use by anyone.
Dr. Jeff Bender - One Health Antibiotic Stewardship Science and Practice - Wh...John Blue
One Health Antibiotic Stewardship Science and Practice - What are the Major Gaps in Knowledge or Translation? How Do We Find the Answers to What We Don't Know? - Dr. Kerry Keffaber, Chief Veterinarian, Scientific Affairs and Policy, Elanco Animal Health; Dr. Jeff Bender, Professor, Environmental Sciences, University of Minnesota; Dr. Nora Schrag, Clinical Assistant Professor/Agricultural Practices, Kansas State University; Mr. Joe Swedberg, Chairman of the Board, Farm Foundation, Hormel Foods Corporation (retired); Dr. David G. White, Associate Dean for Research, University of Tennessee Institute of Agriculture, from the 2017 NIAA Antibiotic Symposium - Antibiotic Stewardship: Collaborative Strategy for Animal Agriculture and Human Health, October 31 - November 2, 2017, Herndon, Virginia, USA.
More presentations at http://www.swinecast.com/2017-niaa-antibiotic-symposium-antibiotic-stewardship
These simplified slides by Dr. Sidra Arshad present an overview of the non-respiratory functions of the respiratory tract.
Learning objectives:
1. Enlist the non-respiratory functions of the respiratory tract
2. Briefly explain how these functions are carried out
3. Discuss the significance of dead space
4. Differentiate between minute ventilation and alveolar ventilation
5. Describe the cough and sneeze reflexes
Study Resources:
1. Chapter 39, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 34, Ganong’s Review of Medical Physiology, 26th edition
3. Chapter 17, Human Physiology by Lauralee Sherwood, 9th edition
4. Non-respiratory functions of the lungs https://academic.oup.com/bjaed/article/13/3/98/278874
Integrating Ayurveda into Parkinson’s Management: A Holistic ApproachAyurveda ForAll
Explore the benefits of combining Ayurveda with conventional Parkinson's treatments. Learn how a holistic approach can manage symptoms, enhance well-being, and balance body energies. Discover the steps to safely integrate Ayurvedic practices into your Parkinson’s care plan, including expert guidance on diet, herbal remedies, and lifestyle modifications.
Recomendações da OMS sobre cuidados maternos e neonatais para uma experiência pós-natal positiva.
Em consonância com os ODS – Objetivos do Desenvolvimento Sustentável e a Estratégia Global para a Saúde das Mulheres, Crianças e Adolescentes, e aplicando uma abordagem baseada nos direitos humanos, os esforços de cuidados pós-natais devem expandir-se para além da cobertura e da simples sobrevivência, de modo a incluir cuidados de qualidade.
Estas diretrizes visam melhorar a qualidade dos cuidados pós-natais essenciais e de rotina prestados às mulheres e aos recém-nascidos, com o objetivo final de melhorar a saúde e o bem-estar materno e neonatal.
Uma “experiência pós-natal positiva” é um resultado importante para todas as mulheres que dão à luz e para os seus recém-nascidos, estabelecendo as bases para a melhoria da saúde e do bem-estar a curto e longo prazo. Uma experiência pós-natal positiva é definida como aquela em que as mulheres, pessoas que gestam, os recém-nascidos, os casais, os pais, os cuidadores e as famílias recebem informação consistente, garantia e apoio de profissionais de saúde motivados; e onde um sistema de saúde flexível e com recursos reconheça as necessidades das mulheres e dos bebês e respeite o seu contexto cultural.
Estas diretrizes consolidadas apresentam algumas recomendações novas e já bem fundamentadas sobre cuidados pós-natais de rotina para mulheres e neonatos que recebem cuidados no pós-parto em unidades de saúde ou na comunidade, independentemente dos recursos disponíveis.
É fornecido um conjunto abrangente de recomendações para cuidados durante o período puerperal, com ênfase nos cuidados essenciais que todas as mulheres e recém-nascidos devem receber, e com a devida atenção à qualidade dos cuidados; isto é, a entrega e a experiência do cuidado recebido. Estas diretrizes atualizam e ampliam as recomendações da OMS de 2014 sobre cuidados pós-natais da mãe e do recém-nascido e complementam as atuais diretrizes da OMS sobre a gestão de complicações pós-natais.
O estabelecimento da amamentação e o manejo das principais intercorrências é contemplada.
Recomendamos muito.
Vamos discutir essas recomendações no nosso curso de pós-graduação em Aleitamento no Instituto Ciclos.
Esta publicação só está disponível em inglês até o momento.
Prof. Marcus Renato de Carvalho
www.agostodourado.com
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
share - Lions, tigers, AI and health misinformation, oh my!.pptxTina Purnat
• Pitfalls and pivots needed to use AI effectively in public health
• Evidence-based strategies to address health misinformation effectively
• Building trust with communities online and offline
• Equipping health professionals to address questions, concerns and health misinformation
• Assessing risk and mitigating harm from adverse health narratives in communities, health workforce and health system
DISSERTATION on NEW DRUG DISCOVERY AND DEVELOPMENT STAGES OF DRUG DISCOVERYNEHA GUPTA
The process of drug discovery and development is a complex and multi-step endeavor aimed at bringing new pharmaceutical drugs to market. It begins with identifying and validating a biological target, such as a protein, gene, or RNA, that is associated with a disease. This step involves understanding the target's role in the disease and confirming that modulating it can have therapeutic effects. The next stage, hit identification, employs high-throughput screening (HTS) and other methods to find compounds that interact with the target. Computational techniques may also be used to identify potential hits from large compound libraries.
Following hit identification, the hits are optimized to improve their efficacy, selectivity, and pharmacokinetic properties, resulting in lead compounds. These leads undergo further refinement to enhance their potency, reduce toxicity, and improve drug-like characteristics, creating drug candidates suitable for preclinical testing. In the preclinical development phase, drug candidates are tested in vitro (in cell cultures) and in vivo (in animal models) to evaluate their safety, efficacy, pharmacokinetics, and pharmacodynamics. Toxicology studies are conducted to assess potential risks.
Before clinical trials can begin, an Investigational New Drug (IND) application must be submitted to regulatory authorities. This application includes data from preclinical studies and plans for clinical trials. Clinical development involves human trials in three phases: Phase I tests the drug's safety and dosage in a small group of healthy volunteers, Phase II assesses the drug's efficacy and side effects in a larger group of patients with the target disease, and Phase III confirms the drug's efficacy and monitors adverse reactions in a large population, often compared to existing treatments.
After successful clinical trials, a New Drug Application (NDA) is submitted to regulatory authorities for approval, including all data from preclinical and clinical studies, as well as proposed labeling and manufacturing information. Regulatory authorities then review the NDA to ensure the drug is safe, effective, and of high quality, potentially requiring additional studies. Finally, after a drug is approved and marketed, it undergoes post-marketing surveillance, which includes continuous monitoring for long-term safety and effectiveness, pharmacovigilance, and reporting of any adverse effects.
2. RHU Sulat AMS Committee
Dr. Rose Teri J. Zacate- Nueva
Municipal Health Officer
Edel A. Aboga-a
Midwife
Main Health Center
Gliceria P. Nival
Pharmacy Aide
Anita L. Orquia
Midwife
BHS Del Remedio
Ma. Belen L. Amit
Midwife
BHS San Isidro
Jessica E. Aclan
AMS Secretariat
Esmeralda N.
Gecomo
Midwife
BHS San Juan
Maria Bibian C.
Yaput
Midwife
BHS San Vicente
Myra A. Rael
BHW
Liason Officer
Ms. Katherine Ann Alday
Medical Technologist
Mr. Joseph Ryan A. Tiu
Public Health Nurse
Glicie Joy P. Nival
Public Health Pharmacist
3. • Leads in implementing and monitoring of AMS activities, and the
evaluation of the AMS program
• Selects and prioritize the antimicrobials to be procured for the RHU
• Educates the staff on appropriate antimicrobial use and health
education activities for the community
• Initiates research activities and treatment patterns of the community
• Does direct patient care and prescribes appropriate medication
regimen per patient need
Municipal Health Officer
• Coordinates, implements and monitors AMS Program, alongside other
national programs
• Assist the MHO in handling and monitoring treatment outcomes of
patients
• Supervises and monitors the midwives and gathers reports to
consolidate data for analysis of outcomes and evaluation of program
Public Health Nurse
4. Municipal Health Officer
•Initiates treatment of basic complaints using IMCI protocols, with the
guidance and supervision of the MHO
•Completes patients’ records and ensure safekeeping of data in the BHS
•Provides community-wide health education on Antimicrobial Stewardship
•Submits monthly report of patient consults and treatment outcomes
•Supervises BHWs who are in-charge of families in monitoring treatment
compliance of patients
Rural Health Midwives
•Assists in coordinating and implementing AMS activities
•Run necessary tests for proper diagnosis and treatment outcomes of the
patients
•Submits AMS reports and examines findings and patterns of illness in the
community to give accurate interpretation and guide future decisions and
choices
Medical Technologist
5. • Coordinates with the MHO, nurses and midwives to ensure timely administration of
appropriate antimicrobials
• Ensures that the right patient is given the right dose of antimicrobials and educates
the patient, pharmacy staff on the proper use of antimicrobials
• Submits timely inventory of crucial medications to ensure sustained delivery of
services
Pharmacist/ Pharmacy Aide
• Provides administrative support to all AMS activities including creating a budget and
other needs for this activities
• Prepares and submits all necessary AMS-related reports and evaluation
AMS Secretariat
• Coordinates closely with Nurses and Midwives in monitoring treatment of patients
• Cascades to fellow BHWs, vital information and monitoring activities
• Does house-to-house visitation of clients on medication to monitor treatment
compliance
• Submits reports to midwife for consolidation in patient records, to note adherence
to treatment, probable side effects and factors affecting compliance, for proper
guidance
Barangay Health Worker/ Liason Officer
6. Succession/Continuity Plan
• All team members can provide
advice on management of
infections, antimicrobial
choice, dosing, administration,
drug interaction, adverse drug
reactions, and allergies
• Ensure that recommendations
are communicated to relevant
staff.
• Determine outputs
and outcomes of
interest.
• Analyze and collect
data.
• Write reports
• Directly communicate
findings to the
relevant committees.
• Educate staff and enforce
compliance to AMS policies,
procedures, guidelines and
pathways.
• Disseminate relevant documents
and ensure they are easily
accessible/visible to all staffs.
• Engage with consumers to
improve knowledge about
antimicrobial therapy.
• Write new guidelines
and amend existing
guidelines when
required.
• Analyze local
specific data and
interpret their
relevance to local
guidelines and adjust
accordingly. Treatment
Guidelines
Continuous
Education
Patient-
Centered
Care
Monitoring
and
Reporting
7. Potential Challenges/Barriers to
Implementation
STAFF REQUIREMENTS
The need for continuous training for MHO on management of common
illnesses and infections
Additional staff for pharmaceutical management
LOGISTICS AND SUPPLIES
Inadequate supply of essential antimicrobials
Prioritization of issues and concerns aside from AMS
PATIENT CONCERNS
Increasing AMR rates
Poor compliance to treatment and self-medication practices
Poor health education about AMR in the community
Belief in quack doctors and inappropriate use of traditional medicines
8. Steps Forward
The AMS committee will lobby for the creation of an ordinance institutionalizing
the AMS policies/protocols. These policies will be made based on the National
Antibiotic Guidelines and AMS Program in PHC Management
The AMS program will be implemented and monitored by AMS Team
Continuous education of all stakeholders and updating of strategies for AMS
Implementation
Regular review of common cases including treatment modality and medication
compliance to the RHU Staff and BHWs
Inclusion of Antimicrobial Stewardship in basic health education sessions in the
community
9. Yours in Health,
AMS Team of RHU Sulat
rhusulat.ams@gmail.com
09424024997/09564431137